Pharma BD Deal Intelligence
Takeda's $310M Intellikine acquisition delivered two kinase programs, but neither paid off under Takeda's ownership: sapanisertib never won approval and was offloaded to Calithera in 2021, while duvelisib—the asset that did reach the market as Copiktra in 2018—had already been bought out by Infinity for $52.5M years before approval.
Takeda's flagship Intellikine asset (sapanisertib) never won approval and was divested to Calithera a decade later; the one asset that did reach FDA approval (duvelisib/Copiktra) had already been bought out of Takeda's hands years earlier for a fixed fee.
Full analysis, sources & comparables →Takeda's Millennium oncology arm picks up two novel kinase inhibitors targeting the PI3K/mTOR pathway, adding clinical-stage depth beyond Velcade.
Factual recap: $190 million upfront with up to $120 million in clinical development milestones for Intellikine's PI3K/mTOR kinase inhibitor portfolio; lead…
Sapanisertib (TAK-228) remained in Phase 2 across breast, endometrial, glioblastoma, renal, and thyroid cancers more than a decade after the Takeda…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Takeda America Holdings agreed to acquire Intellikine for $190M upfront plus up to $120M in milestones (~$310M total). Deal added two novel oncology kinase programs to the Millennium oncology pipeline. Closed Q1 2012.
Takeda's flagship Intellikine asset (sapanisertib) never won approval and was divested to Calithera a decade later; the one asset that did reach FDA approval (duvelisib/Copiktra) had already been bought out of Takeda's hands years earlier for a fixed fee.
Assessment window: 10yr post-close.
$2.3B Global PI3K inhibitor drug-class market by 2033 (forecast)
The PI3K/AKT/mTOR pathway is one of the most frequently activated signaling cascades in human cancer, driving cell growth, survival, and metabolism across breast, endometrial, hematologic, and other tumors. Pathway-selective small-molecule inhibitors of PI3K isoforms and mTOR kinase aim to block tumor growth while sparing normal tissues, but historically have struggled with on-target toxicities (hyperglycemia, rash, GI) limiting therapeutic index.
At deal time (December 2011) the PI3K/mTOR oncology landscape was wide open. Novartis' BYL719 (alpelisib, later Piqray, PI3K-alpha) and Gilead/Calistoga's GS-1101 (idelalisib, PI3K-delta) were the most advanced selective inhibitors, both in Phase 2-3. Pan-PI3K inhibitors (BKM120/buparlisib, GDC-0980, XL147) and dual PI3K/mTOR agents (PF-04691502, GDC-0980) were proliferating. Existing rapalogs Afinitor (everolimus) and Torisel (temsirolimus) addressed mTORC1 only and were the benchmark mTOR therapies. Takeda's Intellikine assets stood out because INK128/MLN0128/sapanisertib was a novel ATP-competitive mTORC1/2 kinase inhibitor differentiated from rapalogs, while INK1117 (later TAK-117/serabelisib) was a selective PI3K-alpha inhibitor competing with alpelisib. Idelalisib went on to win first PI3K oncology approval in 2014, alpelisib in 2019. Sapanisertib advanced through multiple Phase 2 studies in breast, endometrial, renal, and thyroid cancers but never reached approval; Takeda partnered/divested rights and as of 2024 the asset remains in Phase 1/2 thyroid trials with Calithera/Sumitomo. The Intellikine deal validated UCSF kinase chemistry but the program never produced an approval for Takeda.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd. / Intellikine, Inc. (this deal) | 2011 | $310M | 30 |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
| Takeda Pharmaceutical Company Ltd. / Nycomed | 2011 | $13.7B | 72 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
| Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. | 2018 | $1.2B | 64 |
← Browse all deals · How we score deals
More: 2011 deals · Takeda Pharmaceutical Company Ltd. deals · Hematology deals